If exposure to cutting-edge innovations in the healthcare industry is what you’re after, consider the exchange-traded fund highlighted in today’s article, which focuses on potential medical breakthroughs from highly innovative small- and mid-cap companies that have one or more drug candidates in either Phase II or Phase III FDA clinical trials. For more on this ETF, CLICK HERE.